RU2004109786A - METHOD FOR TREATING DISORDERS OF MNESTIC FUNCTIONS - Google Patents

METHOD FOR TREATING DISORDERS OF MNESTIC FUNCTIONS Download PDF

Info

Publication number
RU2004109786A
RU2004109786A RU2004109786/14A RU2004109786A RU2004109786A RU 2004109786 A RU2004109786 A RU 2004109786A RU 2004109786/14 A RU2004109786/14 A RU 2004109786/14A RU 2004109786 A RU2004109786 A RU 2004109786A RU 2004109786 A RU2004109786 A RU 2004109786A
Authority
RU
Russia
Prior art keywords
treating disorders
mnestic functions
mnestic
functions
days
Prior art date
Application number
RU2004109786/14A
Other languages
Russian (ru)
Other versions
RU2268726C2 (en
Inventor
Николай Сергеевич Сапронов (RU)
Николай Сергеевич Сапронов
Николай Андреевич Лосев (RU)
Николай Андреевич Лосев
Юли Олеговна Федотова (RU)
Юлия Олеговна Федотова
Марина Евгеньевна Комова (RU)
Марина Евгеньевна Комова
Original Assignee
ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН (ГУ НИИЭМ РАМН) (RU)
ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН (ГУ НИИЭМ РАМН)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН (ГУ НИИЭМ РАМН) (RU), ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН (ГУ НИИЭМ РАМН) filed Critical ГУ "Научно-исследовательский институт экспериментальной медицины" РАМН (ГУ НИИЭМ РАМН) (RU)
Priority to RU2004109786/14A priority Critical patent/RU2268726C2/en
Publication of RU2004109786A publication Critical patent/RU2004109786A/en
Application granted granted Critical
Publication of RU2268726C2 publication Critical patent/RU2268726C2/en

Links

Claims (1)

Способ лечения нарушения мнестических функций с помощью ингибитора ацетилхолинэстеразы, отличающийся тем, что млекопитающему при ежедневном введении антихолинэстеразного препарата в лечебной дозе дополнительно вводят эстроген в дозе 8-20 мкг/кг ежедневно или регулярно один раз в три дня на протяжении 7-10 сут.A method of treating mnemonic function disorders with an acetylcholinesterase inhibitor, characterized in that the mammal is additionally administered estrogen at a dose of 8-20 μg / kg daily or regularly once every three days for 7-10 days with a daily administration of an anticholinesterase drug.
RU2004109786/14A 2004-03-30 2004-03-30 Method for treating affected amnestic functions RU2268726C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2004109786/14A RU2268726C2 (en) 2004-03-30 2004-03-30 Method for treating affected amnestic functions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2004109786/14A RU2268726C2 (en) 2004-03-30 2004-03-30 Method for treating affected amnestic functions

Publications (2)

Publication Number Publication Date
RU2004109786A true RU2004109786A (en) 2005-09-10
RU2268726C2 RU2268726C2 (en) 2006-01-27

Family

ID=35847672

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004109786/14A RU2268726C2 (en) 2004-03-30 2004-03-30 Method for treating affected amnestic functions

Country Status (1)

Country Link
RU (1) RU2268726C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310968B1 (en) * 2007-06-25 2010-02-08 Italfarmaco, S.A. USE OF ESTRIOL IN LOW DOSE.

Also Published As

Publication number Publication date
RU2268726C2 (en) 2006-01-27

Similar Documents

Publication Publication Date Title
WO2007126964A3 (en) Kinase inhibitors
NO2013017I1 (en) (a) dextromethorphan or a pharmaceutically acceptable salt, precursor or derivative, for example, extromethorphan hydrobromide and especially dextromethorphan hydrobromide monohydrate; and (b) quinidine or a pharmaceutically acceptable salt, precursor or derivative thereof, for example quinidine and especially quinidine sulphate dihydrate
NO20011721D0 (en) N-aralkylaminotetralins as ligands for neuropeptide Y Y5 receptor
PL343771A1 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2006053160A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
EP2479290A3 (en) Methods for the administration of iloperidone
UA90518C2 (en) Pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, comprising a narcotic active ingredient and amine
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
WO2004010936A3 (en) Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
WO2006033891A3 (en) Compounds for the treatment of dyslipidemia and other lipid disorders
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
ATE319473T1 (en) MELAGATRAN FOR THE TREATMENT OF INFLAMMATION
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
NO20031410L (en) Use of distamycin derivatives for the manufacture of drugs
EP1741430A4 (en) Remedy for psychoneurotic diseases
RU2004109786A (en) METHOD FOR TREATING DISORDERS OF MNESTIC FUNCTIONS
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders
DK1183046T3 (en) Aminotetralin derivative for the treatment of cardiovascular diseases
MX2007012991A (en) Crystalline solid and amorphous forms of (-)- halofenate.
ATE477021T1 (en) 1,3,5-TRIAZEPINE DIONE FOR THE TREATMENT OF MALARIA

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20060331